Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2023-05, Vol.25 (5), p.1398-1402
Hauptverfasser:	Kim, Joseph M., Bhatt, Deepak L., Dagogo‐Jack, Samuel, Cherney, David Z. I., Cosentino, Francesco, McGuire, Darren K., Pratley, Richard E., Liu, Chih‐Chin, Cater, Nilo B., Frederich, Robert, Mancuso, James P., Cannon, Christopher P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Arteriosclerosis Atherosclerosis Atherosclerosis - complications Atherosclerosis - drug therapy Atherosclerosis - prevention & control Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control cardiovascular risk reduction Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Eicosapentaenoic Acid Heart Disease Risk Factors Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypertriglyceridemia icosapent ethyl Medicin och hälsovetenskap REDUCE‐IT Risk Factors type 2 diabetes VERTIS CV
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!